Mengis Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.8M | Sell |
70,648
-100
| -0.1% | -$15.3K | 1.86% | 10 |
|
|
2025
Q4 | $9.75M | Buy |
70,748
+6,750
| +11% | +$884K | 1.72% | 13 |
|
|
2025
Q3 | $8.21M | Sell |
63,998
-485
| -0.8% | -$59.2K | 1.61% | 14 |
|
|
2025
Q2 | $7.8M | Sell |
64,483
-15,630
| -20% | -$1.76M | 1.66% | 15 |
|
|
2025
Q1 | $8.93M | Hold |
80,113
| – | – | 1.86% | 11 |
|
|
2024
Q4 | $7.8M | Buy |
80,113
+600
| +0.8% | +$64K | 1.59% | 14 |
|
|
2024
Q3 | $9.15M | Sell |
79,513
-2,092
| -3% | -$237K | 1.8% | 13 |
|
|
2024
Q2 | $8.69M | Sell |
81,605
-2,188
| -3% | -$220K | 1.76% | 13 |
|
|
2024
Q1 | $8.11M | Buy |
83,793
+1,850
| +2% | +$190K | 1.25% | 18 |
|
|
2023
Q4 | $8.27M | Buy |
81,943
+300
| +0.4% | +$29K | 1.55% | 15 |
|
|
2023
Q3 | $8.32M | Sell |
81,643
-50
| -0.1% | -$5.08K | 1.73% | 15 |
|
|
2023
Q2 | $8.24M | Sell |
81,693
-175
| -0.2% | -$17.5K | 1.64% | 15 |
|
|
2023
Q1 | $7.53M | Sell |
81,868
-390
| -0.5% | -$34.1K | 1.59% | 15 |
|
|
2022
Q4 | $7.46M | Sell |
82,258
-470
| -0.6% | -$39.6K | 1.63% | 16 |
|
|
2022
Q3 | $6.29M | Sell |
82,728
-3,133
| -4% | -$260K | 1.49% | 16 |
|
|
2022
Q2 | $7.26M | Sell |
85,861
-135
| -0.2% | -$11.8K | 1.59% | 15 |
|
|
2022
Q1 | $7.55M | Buy |
85,996
+967
| +1% | +$83.7K | 1.45% | 16 |
|
|
2021
Q4 | $7.44M | Buy |
85,029
+2,350
| +3% | +$195K | 1.4% | 16 |
|
|
2021
Q3 | $6.76M | Buy |
82,679
+250
| +0.3% | +$22.5K | 1.42% | 18 |
|
|
2021
Q2 | $7.52M | Buy |
82,429
+1,687
| +2% | +$150K | 1.56% | 16 |
|
|
2021
Q1 | $6.9M | Buy |
80,742
+7,373
| +10% | +$662K | 1.53% | 17 |
|
|
2020
Q4 | $6.93M | Buy |
73,369
+44
| +0.1% | +$3.85K | 1.68% | 13 |
|
|
2020
Q3 | $6.38M | Buy |
73,325
+1,233
| +2% | +$107K | 1.75% | 14 |
|
|
2020
Q2 | $6.3M | Buy |
72,092
+22
| +0% | +$1.9K | 1.87% | 11 |
|
|
2020
Q1 | $5.94M | Buy |
72,070
+3,440
| +5% | +$307K | 2.03% | 10 |
|
|
2019
Q4 | $6.5M | Sell |
68,630
-333
| -0.5% | -$29.9K | 1.79% | 11 |
|
|
2019
Q3 | $5.99M | Sell |
68,963
-50
| -0.1% | -$4.49K | 1.79% | 10 |
|
|
2019
Q2 | $6.3M | Buy |
69,013
+39,729
| +136% | +$3.36M | 1.93% | 8 |
|
|
2019
Q1 | $2.52M | Sell |
29,284
-78
| -0.3% | -$6.26K | 1.41% | 24 |
|
|
2018
Q4 | $2.26M | Sell |
29,362
-112
| -0.4% | -$8.72K | 1.43% | 23 |
|
|
2018
Q3 | $2.27M | Sell |
29,474
-306
| -1% | -$22.6K | 1.25% | 24 |
|
|
2018
Q2 | $2.02M | Buy |
29,780
+55
| +0.2% | +$3.79K | 1.19% | 24 |
|
|
2018
Q1 | $2.15M | Hold |
29,725
| – | – | 1.29% | 25 |
|
|
2017
Q4 | $2.24M | Buy |
29,725
+837
| +3% | +$63.2K | 1.35% | 24 |
|
|
2017
Q3 | $2.22M | Buy |
28,888
+1,228
| +4% | +$92.7K | 1.49% | 24 |
|
|
2017
Q2 | $2.07M | Buy |
27,660
+3,365
| +14% | +$238K | 1.46% | 24 |
|
|
2017
Q1 | $1.62M | Buy |
+24,295
| New | +$1.62M | 1.18% | 27 |
|
Other funds holding NVS
Mengis Capital Management's NVS Position: Q1 2026 in Review
Mengis Capital Management reduced its Novartis (NVS) stake by 0.14% in Q1 2026, selling an estimated $15.3K and leaving 70,648 shares worth $10.8M. The position accounts for 1.86% of the portfolio, ranked #10.
Mengis Capital Management first reported a position in NVS in Q1 2017 and has held it in 37 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Mengis Capital Management held 70,648 shares of Novartis worth $10.8M as of Q1 2026.
- Mengis Capital Management sold 100 Novartis shares in Q1 2026, an estimated $15.3K.
- Novartis made up 1.86% of Mengis Capital Management's portfolio in Q1 2026, its #10 holding.
- Mengis Capital Management first reported a position in Novartis in Q1 2017 and has held it in 37 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.